K
Kevin M. Chin
Researcher at Merck Serono
Publications - 64
Citations - 6091
Kevin M. Chin is an academic researcher from Merck Serono. The author has contributed to research in topics: Ipilimumab & Avelumab. The author has an hindex of 26, co-authored 62 publications receiving 5249 citations. Previous affiliations of Kevin M. Chin include Bristol-Myers Squibb & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D. Wolchok,Bart Neyns,Gerald P. Linette,Sylvie Negrier,Jose Lutzky,Luc Thomas,William Waterfield,Dirk Schadendorf,Michael Smylie,Troy H. Guthrie,Jean-Jacques Grob,Jason Chesney,Kevin M. Chin,Kun Chen,Axel Hoos,Steven J. O'Day,Céleste Lebbé +16 more
TL;DR: Ipilimumab elicited a dose-dependent effect on efficacy and safety measures in pretreated patients with advanced melanoma, lending support to further studies at a dose of 10 mg/kg.
Journal ArticleDOI
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman,Jeffery S. Russell,Omid Hamid,Shailender Bhatia,Patrick Terheyden,Sandra P. D'Angelo,Kent C. Shih,Céleste Lebbé,Gerald P. Linette,Michele Milella,Isaac Brownell,Karl D. Lewis,Jochen H. Lorch,Kevin M. Chin,Lisa Mahnke,Anja von Heydebreck,Jean Marie Cuillerot,Paul Nghiem +17 more
TL;DR: Treatment with avelumab was associated with durable responses, most of which are still ongoing, and was well tolerated; hence, a Velumab represents a new therapeutic option for advanced Merkel cell carcinoma.
Journal ArticleDOI
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
Luc Dirix,István Takács,Guy Jerusalem,Petros Nikolinakos,Hendrik Tobias Arkenau,Hendrik Tobias Arkenau,Andres Forero-Torres,Ralph V. Boccia,Marc E. Lippman,Robert Somer,Martin Smakal,Leisha A. Emens,Borys Hrinczenko,William Jeffery Edenfield,Jayne S. Gurtler,Anja von Heydebreck,Hans Juergen Grote,Kevin M. Chin,Erika Hamilton +18 more
TL;DR: PD-L1 expression in tumor-associated immune cells may be associated with a higher probability of clinical response to avelumab in MBC, and showed an acceptable safety profile and clinical activity in a subset of patients with MBC.
Journal ArticleDOI
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
Susan F. Slovin,Celestia S. Higano,Omid Hamid,Sheela Tejwani,Andrea L. Harzstark,Joshi J. Alumkal,Howard I. Scher,Kevin M. Chin,Paul Gagnier,M.B. McHenry,Tomasz M. Beer +10 more
TL;DR: In mCRPC patients, ipilimumab 10 mg/kg ± radiotherapy suggested clinical antitumor activity with disease control and manageable AEs.
Journal ArticleDOI
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.
Andrea B. Apolo,Jeffrey R. Infante,Ani Sarkis Balmanoukian,Manish R. Patel,Ding Wang,Karen Kelly,Anthony Mega,Carolyn D. Britten,Alain Ravaud,Alain C. Mita,Howard Safran,Thomas E. Stinchcombe,Marko Srdanov,Arnold B. Gelb,Michael Schlichting,Kevin M. Chin,James L. Gulley +16 more
TL;DR: Avelumab was well tolerated and associated with durable responses and prolonged survival in patients with refractory metastatic metastatic UC and PD-L1–associated clinical activity.